AACR: Hansoh’s ADC Impresses In IO Combo For 2L NSCLC

 
• By Dexter Jie Yan
  
The second-line therapeutic options following progression on standard-of-care immunochemotherapies remain limited. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Trial Results

More from R&D